QuidelOrtho, a diagnostic company, is looking into the possibility of selling its testing unit. This move comes as the company faces a dramatic decline in its stock value.
The company's shares have decreased by 90% since it received the first approval for its rapid antigen tests for Covid-19. This significant drop raises concerns about its market position.
As private equity firms show interest in healthcare companies, QuidelOrtho's potential sale could attract attention. However, the future remains uncertain as the company navigates this challenging landscape.